Cargando…

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Tadeusz, Korycka, Anna, Lech-Maranda, Ewa, Robak, Pawel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253893/
https://www.ncbi.nlm.nih.gov/pubmed/19325518
http://dx.doi.org/10.3390/molecules14031183
_version_ 1783373598678843392
author Robak, Tadeusz
Korycka, Anna
Lech-Maranda, Ewa
Robak, Pawel
author_facet Robak, Tadeusz
Korycka, Anna
Lech-Maranda, Ewa
Robak, Pawel
author_sort Robak, Tadeusz
collection PubMed
description For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials.
format Online
Article
Text
id pubmed-6253893
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Molecular Diversity Preservation International
record_format MEDLINE/PubMed
spelling pubmed-62538932018-11-30 Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases Robak, Tadeusz Korycka, Anna Lech-Maranda, Ewa Robak, Pawel Molecules Review For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials. Molecular Diversity Preservation International 2009-03-23 /pmc/articles/PMC6253893/ /pubmed/19325518 http://dx.doi.org/10.3390/molecules14031183 Text en © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Robak, Tadeusz
Korycka, Anna
Lech-Maranda, Ewa
Robak, Pawel
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
title Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
title_full Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
title_fullStr Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
title_full_unstemmed Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
title_short Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
title_sort current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253893/
https://www.ncbi.nlm.nih.gov/pubmed/19325518
http://dx.doi.org/10.3390/molecules14031183
work_keys_str_mv AT robaktadeusz currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases
AT koryckaanna currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases
AT lechmarandaewa currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases
AT robakpawel currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases